Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug ER-100 tested for eye nerve damage – first human trial begins

NCT ID NCT07290244

First seen Jan 09, 2026 · Last updated May 19, 2026 · Updated 30 times

Summary

This early-stage study tests whether a single dose of ER-100 is safe for adults with open-angle glaucoma or a type of optic nerve stroke called NAION. Researchers will monitor side effects, eye health, and vision over up to 5 years. The goal is to find a safe dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPEN ANGLE GLAUCOMA (OAG) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Charleston Neuroscience Institute

    RECRUITING

    Charleston, South Carolina, 29414, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Columbia University Irving Medical Center/Edward S. Harkness Eye Institute

    RECRUITING

    New York, New York, 10032, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Global Research Management, Inc.

    RECRUITING

    Glendale, California, 91204, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mass Eye and Ear

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.